[FDA Approval. Photo Credit to Picryl]

On October 20, 2026, the U.S. Food and Drug Administration (FDA) approved Hibsago (bepirovirsen), a landmark treatment for chronic hepatitis B co-developed by GSK and Ionis Pharmaceuticals.

The regulatory approval introduces a finite six-month therapeutic regimen that offers select eligible adult patients with chronic hepatitis B the potential opportunity to achieve a functional cure — a clinical milestone previously considered out of reach for the vast majority of individuals living with the lifelong condition.

Hepatitis B is a highly contagious and severe viral infection that targets human liver cells.

Left unchecked, the virus causes chronic organ inflammation, progressive hepatic tissue scarring, and a significantly heightened long-term risk of developing severe end-stage liver complications, including cirrhosis and primary liver cancer (hepatocellular carcinoma).

Globally, an estimated 240 million people live with chronic hepatitis B, creating a persistent public health challenge worldwide.

For decades, developing a durable cure for chronic hepatitis B has presented an extraordinary biological challenge for biomedical researchers.

Once the virus establishes a foothold inside host hepatocytes, it continuously replicates and manufactures vast quantities of viral proteins.

Among these, the hepatitis B surface antigen (HBsAg) circulates in the patient's bloodstream at exceptionally high concentrations, overwhelming the host environment.

This relentless flood of viral proteins acts as an effective immune suppressor, contributing to the exhaustion and impairment of the host's natural immune defenses.

Over time, immune cells lose their capacity to recognize or mount an effective targeted response against the pathogen, allowing the chronic infection to persist indefinitely within the body.

What distinguishes Hibsago from previous therapeutic options is its targeted genetic mechanism of action.

Hibsago belongs to an innovative therapeutic class known as antisense oligonucleotides, which are designed to act as targeted biological interceptors inside human liver cells.

Rather than inhibiting viral replication after new viral particles have already been synthesized, Hibsago directly binds to and promotes the degradation of specific messenger RNA (mRNA) instructions that the virus relies on to produce its proteins.

By systematically lowering the concentration of circulating viral surface antigens, Hibsago reduces the viral protein burden that suppresses the immune function.

This reduction helps create optimal clinical conditions under which the host's own immune system can better recognize and exert immune control over the viral infection.

Prior to Hibsago’s approval, managing chronic hepatitis B required patients to take daily oral nucleos(t)ide analogues (NAs) indefinitely to maintain viral suppression and prevent organ damage. 

However, existing standard therapies achieve a functional cure — where hepatitis B surface antigen and viral DNA remain undetectable in the blood even after stopping medication — in fewer than 1% of treated patients.

Under the newly approved protocol, Hibsago is administered as a structured 24-week course of weekly subcutaneous injections in combination with ongoing background oral nucleos(t)ide analogue therapy.

Crucially, Hibsago is designed to be used alongside existing antivirals rather than as an immediate standalone replacement.

For certain patients who achieve sustained viral antigen reduction, the combination regimen provides a clinical framework where physicians can evaluate whether oral antiviral treatment might eventually be discontinued safely, though therapeutic cessation will not be suitable for every patient completing the 24-week course.

In pivotal Phase 3 clinical trials, 19% of all participating patients achieved a functional cure six months after concluding the 24-week treatment regimen.

Notably, that rate increased to 26% among a specific subgroup of patients who initiated treatment with lower baseline levels of viral surface antigen.

Despite these promising clinical outcomes, Hibsago necessitates meticulous medical monitoring and clinical precautions.

Patients undergoing treatment must receive routine blood monitoring due to documented risks of transient liver enzyme spikes (ALT flares) and sudden drops in blood platelet counts (thrombocytopenia).

Additionally, the drug is not currently approved for patients who have already developed advanced liver scarring, known as cirrhosis.

The regulatory decision for Hibsago marks a significant therapeutic advancement in the chronic hepatitis B landscape.

Within the biopharmaceutical industry, it also serves as a meaningful proof of concept for antisense oligonucleotide technology, illustrating that targeting viral RNA transcripts can effectively reduce viral protein expression in persistent chronic infections.

For clinicians and the millions of individuals living with chronic hepatitis B worldwide, Hibsago provides a specialized new option that advances disease management.

While further real-world research will determine its broader long-term applicability across diverse patient populations, the approval marks a shift toward finite targeted interventions and offers renewed clinical promise for eligible patient groups.